Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases

Autor: Dam, K.P.J. van, Volkers, A.G., Wieske, L., Stalman, E.W., Kummer, L.Y.L., Kempen, Z.L.E. van, Killestein, J., Tas, S.W., Boekel, L., Wolbink, G.J., Kooi, A.J. van der, Raaphorst, J., Takkenberg, R.B., D'Haens, G.R.A.M.I., Spuls, P.W., Bekkenk, M.H., Musters, A.F., Post, N.L., Bosma, A.L., Hilhorst, M., Vegting, Y.J., Bemelman, F.E., Voskuyl, A., Broens, B., Sanchez, A.P., Els, C.A.C.M. van, Wit, J. de, Rutgers, A., Leeuw, K. de, Horvath, B., Verschuuren, J.J.G.M.M., Ruiter, A.M., Ouwerkerk, L. van, Woude, D. van der, Allaart, R.C.F., Teng, Y.K.O., Paassen, P.H. van, Busch, M.H., Jallah, P.B.P., Brusse, E., Doorn, P.A. van, Baars, A.E., Hijnen, D.J., Schreurs, C.R.G., Pol, W.L. van der, Goedee, H.S., Steenhuis, M., Keijzer, S., Keijser, J.B.D., Cristianawati, O., Brinke, A. ten, Verstegen, N.J.M., Ham, S.M. van, Rispens, T.W., Kuijpers, T., Lowenberg, M., Eftimov, F., TB2 Immunity Sars-Cov-2 Study Grp

Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term hum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::48e652b90d3e035b57aa8ad553b7a0eb
https://hdl.handle.net/1887/3630357

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

Autor: Stalman, E.W., Wieske, L., Dam, K.P.J. van, Kummer, L.Y., Kempen, Z.L.E. van, Killestein, J., Volkers, A.G., Tas, S.W., Boekel, L., Wolbink, G.J., Kooi, A.J. van der, Raaphorst, J., Lowenberg, M., Takkenberg, R.B., D'Haens, G.R.A.M., Spuls, P.I., Bekkenk, M.W., Musters, A.H., Post, N.F., Bosma, A.L., Hilhorst, M.L., Vegting, Y., Bemelman, F.J., Voskuyl, A.E., Broens, B., Sanchez, A.P., Els, C.A.C.M. van, Wit, J. de, Rutgers, A., Leeuw, K. de, Horvath, B., Verschuuren, J.J.G.M., Ruiter, A.M., Ouwerkerk, L. van, Woude, D. van der, Allaart, C.F., Teng, O.Y.K., Paassen, P. van, Busch, M.H., Jallah, P.B.P., Brusse, E., Doorn, P.A. van, Baars, A.E., Hijnen, D.J., Schreurs, C.R.G., Pol, W.L. van der, Goedee, H.S., Steenhuis, M., Keijzer, S., Keijser, J.B.D., Boogaard, A., Cristianawati, O., Brinke, A. ten, Verstegen, N.J.M., Zwinderman, K.A.H., Rispens, T., Ham, S.M. van, Kuijpers, T.W., Eftimov, F., T2B Immunity Against SARS Co

Publikováno v: Annals of the Rheumatic Diseases, 81(12):222904, 1757-1766. BMJ Publishing Group
Annals of the rheumatic diseases, 81(12):222904, 1757-1766. BMJ Publishing Group
Annals of the Rheumatic Diseases, 81, 1757-1766. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 81(12), 1757-1766. BMJ Publishing Group
Stalman, E W, Wieske, L, van Dam, K P J, Kummer, L Y, van Kempen, Z L E, Killestein, J, Volkers, A G, Tas, S W, Boekel, L, Wolbink, G J, van der Kooi, A J, Raaphorst, J, Löwenberg, M, Takkenberg, R B, D'Haens, G R A M, Spuls, P I, Bekkenk, M W, Musters, A H, Post, N F, Bosma, A L, Hilhorst, M L, Vegting, Y, Bemelman, F J, Voskuyl, A E, Broens, B, Parra Sanchez, A, van Els, C C A C M, Wit, J D, Rutgers, A, de Leeuw, K, Horváth, B, Verschuuren, J J G M, Ruiter, A M, van Ouwerkerk, L, van der Woude, D, Allaart, C F, Teng, O Y K, van Paassen, P, Busch, M H, Jallah, P B P, Brusse, E, van Doorn, P A, Baars, A E, Hijnen, D J, Schreurs, C R G, van der Pol, W L, Goedee, H S, Steenhuis, M, Keijzer, S, Keijser, J B D, Boogaard, A, Cristianawati, O, ten Brinke, A, Verstegen, N J M, Zwinderman, K A H, Rispens, T, van Ham, S M, Kuijpers, T W & Eftimov, F 2022, ' Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases ', Annals of the Rheumatic Diseases, vol. 81, no. 12, 222904, pp. 1757-1766 . https://doi.org/10.1136/ard-2022-222904
Annals of the Rheumatic Diseases, 81(12). BMJ PUBLISHING GROUP

ObjectivesTo compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19dc8c343aa3a7c58690faa029528df1
https://pure.eur.nl/en/publications/95be4c3a-8d51-4bec-a116-f9d40c9a985a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.